A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D

NCT01222884 | Completed Phase 3 Results

• 1 other identifier: P-Monofer-CKD-03
• Study Type: interventional
• Target: 351
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the efficacy and safety of intravenous iron isomaltoside 1000 with intravenous iron sucrose in patients suffering from Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).

Conditions

Chronic Kidney Disease Stage 5 (Dialysis Dependent)

Outcome Measures

Primary Outcomes (1)

• Ability to Maintain Hemoglobin Level

  The primary outcome measure was the proportion of subjects who were able to maintain haemoglobin between 9.5 and 12.5 g/dL (both values included) at week 6. Haemoglobin was measured by a blood sample at the different visits. All blood samples were taken before the dialysis from the dialysis catheter. Intravenous iron was administered during dialysis, at least 30 min after the start and at least 1 h before the end of dialysis.

  Baseline to 6 weeks

Secondary Outcomes (1)

• Change in Hemoglobin Concentration

  6 weeks

Study Arms (2)

Iron isomaltoside 1000

ACTIVE COMPARATOR

Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection

Drug: Monofer

Iron sucrose

ACTIVE COMPARATOR

Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection

Drug: Iron sucrose

Interventions

Monofer DRUG

Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes

Iron isomaltoside 1000

Iron sucrose DRUG

Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics

Iron sucrose

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men or women, aged 18 years or greater.
• Subjects diagnosed with CKD-5D and in haemodialysis therapy for at least 90 days.
• Life expectancy beyond 12 months by Principal Investigator's judgement.
• Willingness and ability to participate after Informed Consent.
• Hb concentrations between 9.5 g/dL and 12.5 g/dL (both values included) both at Screening Visit 1a and at Screening Visit 1b (screening Visit 1a and Visit 1b must be separated by at least 1 week).
• Serum ferritin \< 800 ng/mL.
• Transferrin Saturation \< 35%.
• Subjects receiving ESA treatment with dose stable for the previous 4 weeks prior to screening (with only 1 missed dose to be allowed. Dose to be kept stable during the study period).
• Subjects receiving no IV iron or an average of no more than 100 mg/week for the previous 4 weeks (with only 1 missed dose to be allowed).

You may not qualify if:

• Anaemia caused primarily by factors other than renal related anaemia.
• Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
• Patients currently undergoing treatment with immunosuppresives (low dose steroids are allowed during the study conduct for dosages no more than 10 mg prednisolone/day or equivalent. If possible the dosage should be kept constant through the study).
• Difference of Hb ≥ 1.0 g/dL between screening (Visits 1a and 1b).
• Patients with a history of multiple allergies.
• Decompensated liver cirrhosis or active hepatitis \[Alanine Aminotransferase (ALT) \> 3 times normal\] or history of Hepatitis B or C.
• Active acute or chronic infections (assessed by clinical judgement), supplied with White Blood Cells (WBC) and C - reactive protein (CRP).
• Rheumatoid arthritis with symptoms or signs of active joint inflammation.
• Pregnancy or nursing. \[To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, Intrauterine Devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches\]
• Blood transfusion within the previous 12 weeks.
• Planned elective surgery in the next 8 weeks.
• Participation in any other clinical trial within the past 30 days, or if longer, where the study drug has not passed five half-lives prior to screening.
• Untreated Vitamin B12 or folate deficiency.
• Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Examples include Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.

Sponsors & Collaborators

• Pharmacosmos A/S: lead

Study Sites (1)

Jatin Kothari

Mumbai, India

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Ferric Oxide, Saccharated

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Ferric Compounds; Iron Compounds; Inorganic Chemicals; Glucaric Acid; Sugar Acids; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Hydroxy Acids; Carbohydrates

Results Point of Contact

• Title: Vice President Research & Development Department
• Organization: Pharmacosmos A/S

llt@pharmacosmos.com

+45 59485959

Study Officials

• Lars Lykke Thomsen, MD

  Pharmacosmos A/S

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 15, 2010
• First Posted: October 18, 2010
• Study Start: June 1, 2011
• Primary Completion: October 1, 2013
• Study Completion: December 1, 2013
• Last Updated: December 2, 2015
• Results First Posted: July 24, 2015

Record last verified: 2015-06

Locations

IN (1)